920 related articles for article (PubMed ID: 27378134)
1. Chronic Prostate Inflammation is Associated with Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention.
Nickel JC; Roehrborn CG; Castro-Santamaria R; Freedland SJ; Moreira DM
J Urol; 2016 Nov; 196(5):1493-1498. PubMed ID: 27378134
[TBL] [Abstract][Full Text] [Related]
2. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
[TBL] [Abstract][Full Text] [Related]
3. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
[TBL] [Abstract][Full Text] [Related]
4. Baseline Basal Cell Hyperplasia Is not Associated With Baseline Lower Urinary Tract Symptoms, Baseline Clinical Prostatitis or Prostate Cancer in Repeat Biopsies.
Freitas D; Andriole GL; Freedland SJ; Neto BS; Moreira DM
Urology; 2019 Jul; 129():160-164. PubMed ID: 30914334
[TBL] [Abstract][Full Text] [Related]
5. Understanding Treatment Response in Individual Profiles of Men with Prostatic Enlargement at Risk of Progression.
Gravas S; Palacios-Moreno JM; Thompson D; Concas F; Kamola PJ; Roehrborn CG; Oelke M; Kattan MW; Averbeck MA; Manyak M; Cortés V; Lulic Z
Eur Urol Focus; 2023 Jan; 9(1):178-187. PubMed ID: 35985933
[TBL] [Abstract][Full Text] [Related]
6. Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study.
Toren P; Margel D; Kulkarni G; Finelli A; Zlotta A; Fleshner N
BMJ; 2013 Apr; 346():f2109. PubMed ID: 23587564
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia.
McVary KT; Roehrborn CG; Chartier-Kastler E; Efros M; Bugarin D; Chen R; Patel A; Haag-Molkenteller C
J Urol; 2014 Jul; 192(1):150-6. PubMed ID: 24508634
[TBL] [Abstract][Full Text] [Related]
8. Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.
Simon RM; Howard LE; Moreira DM; Roehrborn C; Vidal AC; Castro-Santamaria R; Freedland SJ
Eur Urol; 2016 May; 69(5):885-91. PubMed ID: 26724841
[TBL] [Abstract][Full Text] [Related]
9. Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study.
Feng T; Howard LE; Vidal AC; Moreira DM; Castro-Santamaria R; Andriole GL; Freedland SJ
Int J Urol; 2017 Feb; 24(2):151-156. PubMed ID: 28004415
[TBL] [Abstract][Full Text] [Related]
10. Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: What Is the Role and Significance of Inflammation?
Lloyd GL; Marks JM; Ricke WA
Curr Urol Rep; 2019 Aug; 20(9):54. PubMed ID: 31377881
[TBL] [Abstract][Full Text] [Related]
11. Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE.
Simon RM; Howard LE; Moreira DM; Roehrborn C; Vidal A; Castro-Santamaria R; Freedland SJ
J Urol; 2017 Sep; 198(3):650-656. PubMed ID: 28428110
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
13. Incidence and risk of treatment for benign prostatic hyperplasia in Japanese men: a 15-year longitudinal community-based study.
Fukuta F; Masumori N; Mori M; Tsukamoto T
Int J Urol; 2013 Jan; 20(1):100-6. PubMed ID: 23106204
[TBL] [Abstract][Full Text] [Related]
14. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH).
Gandaglia G; Briganti A; Gontero P; Mondaini N; Novara G; Salonia A; Sciarra A; Montorsi F
BJU Int; 2013 Aug; 112(4):432-41. PubMed ID: 23650937
[TBL] [Abstract][Full Text] [Related]
15. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.
Brock GB; McVary KT; Roehrborn CG; Watts S; Ni X; Viktrup L; Wong DG; Donatucci C
J Urol; 2014 Feb; 191(2):405-11. PubMed ID: 24096120
[TBL] [Abstract][Full Text] [Related]
16. Is the presence of varicocele associated with static and dynamic components of benign prostatic hyperplasia/lower urinary tract symptoms in elderly men?
Otunctemur A; Ozbek E; Besiroglu H; Dursun M; Sahin S; Koklu I; Erkoc M; Danis E; Bozkurt M; Gurbuz A
Int J Urol; 2014 Dec; 21(12):1268-72. PubMed ID: 25056570
[TBL] [Abstract][Full Text] [Related]
17. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.
Gittelman M; Ramsdell J; Young J; McNicholas T
J Urol; 2006 Sep; 176(3):1045-50; discussion 1050. PubMed ID: 16890688
[TBL] [Abstract][Full Text] [Related]
18. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
Yokoyama O; Yoshida M; Kim SC; Wang CJ; Imaoka T; Morisaki Y; Viktrup L
Int J Urol; 2013 Feb; 20(2):193-201. PubMed ID: 22958078
[TBL] [Abstract][Full Text] [Related]
19. Sleep Problems are Associated with Development and Progression of Lower Urinary Tract Symptoms: Results from REDUCE.
Branche BL; Howard LE; Moreira DM; Roehrborn C; Castro-Santamaria R; Andriole GL; Hopp ML; Freedland SJ
J Urol; 2018 Feb; 199(2):536-542. PubMed ID: 28870861
[TBL] [Abstract][Full Text] [Related]
20. Prostate Biopsy Markers of Inflammation are Associated with Risk of Clinical Progression of Benign Prostatic Hyperplasia: Findings from the MTOPS Study.
Torkko KC; Wilson RS; Smith EE; Kusek JW; van Bokhoven A; Lucia MS
J Urol; 2015 Aug; 194(2):454-61. PubMed ID: 25828974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
